Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BloomWell Rx vs GoodRx

BloomWell Rx
Graded #296

Lower grade

vs+8.299999999999997
GoodRx
Graded #116

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 61.3/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +26
54
80
Dose & formulationGoodRx +6
64
70
Clinical oversightBloomWell Rx +2
71
69
Labs & monitoringBloomWell Rx +2
53
51
FulfillmentGoodRx +11
70
81
Contract termsEven
55
55
BloomWell Rx · left barGoodRx · right bar

The numbers

MetricBloomWell RxGoodRx
WeighScore61.3/10069.6/100
GradeCC
Scorecard rank#296#116
Semaglutide$199/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (starting dose, compounded)$299/mo (brand Zepbound)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
BloomWell Rx

Graded #296 · C

Strengths

  • Transparent pricing — compounded semaglutide from $199/mo, tirzepatide (GLP-1/GIP) from $249/mo
  • Free initial visit; fully online process with flexible dosing options
  • Discloses meds are compounded by a licensed third-party pharmacy; also offers NAD+, sermorelin, glutathione
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)

Where it loses points

  • 'Starts at' pricing — final cost depends on dose and plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • Not LegitScript-certified (no certification displayed)
  • Operating medical entity not clearly named (site operated by a marketing agency)
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard